LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported results for the second quarter ended June 30, 2007. Net sales of CUBICIN® (daptomycin for injection) increased 52% from the prior year, from $45.7 million in the second quarter of 2006 to $69.5 million in the second quarter of 2007. U.S. net product revenue was $68.3 million. Total revenues for the second quarter of 2007 increased 46% over the second quarter of 2006 from $47.8 million in the second quarter of 2006 to $69.8 million in the second quarter of 2007.
